Immedica Pharma
Immedica Pharma, a prominent player in the pharmaceutical industry, is headquartered in Sweden (SE) and operates extensively across Europe and the Middle East. Founded in 2010, the company has rapidly established itself as a leader in the development and commercialisation of innovative therapies, particularly in the fields of rare diseases and specialty pharmaceuticals. Immedica Pharma is renowned for its unique portfolio of products, which includes advanced treatments that address unmet medical needs. The company’s commitment to quality and patient-centric solutions has garnered significant recognition within the healthcare community. With a strong market position, Immedica continues to expand its reach, driven by a dedication to improving patient outcomes and enhancing the quality of life for those affected by challenging health conditions.
DitchCarbon Score
How does Immedica Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Immedica Pharma's score of 15 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Immedica Pharma's reported carbon emissions
In 2023, Immedica Pharma reported total carbon emissions of approximately 2,783,000 kg CO2e, all of which fall under Scope 3 emissions, specifically from purchased goods and services, which accounted for about 26,555,000 kg CO2e. In the previous year, 2022, the company recorded Scope 3 emissions of about 2,129,000 kg CO2e, indicating an increase in emissions. Notably, Immedica Pharma has not disclosed any Scope 1 or Scope 2 emissions, both of which were reported as zero. The company currently does not have any specific reduction targets or climate pledges in place, which suggests a potential area for future commitment to sustainability and emissions reduction. Overall, while Immedica Pharma's emissions are primarily from indirect sources, the absence of reduction initiatives highlights an opportunity for the company to enhance its climate strategy and align with industry standards for carbon management.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | 2,129,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Immedica Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
